Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 1.00 |
| ▸ | MMP9 | P14780 | 16/20 | 1.00 |
| ▸ | MMP8 | P22894 | 14/20 | 1.00 |
| ▸ | MMP1 | P03956 | 7/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 1.00 |
| ▸ | MMP14 | P50281 | 2/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 1/20 | 1.00 |
| ▸ | ADAM12 | O43184 | 1/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 1.00 |
| ▸ | MMP7 | P09237 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
| ▸ | MMP15 | P51511 | 1/20 | 1.00 |
| ▸ | MMP16 | P51512 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | ADAM9 | Q13443 | 1/20 | 1.00 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 1.00 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 1.00 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilomastat SCHEMBL29412562 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL7870487 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL6691646 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL8190117 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL35303 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL13575799 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL4293696 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8394283 | 0.92 | MMP2 (0.85) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL4845965 | 0.91 | MMP2 (0.84) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL5558468 | 0.90 | MMP2 (0.82) | MMP2MMP9MMP8MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | claimed |
| US-20090299466-A1 | Local Delivery of Matrix Metalloproteinase Inhibitors | MEDTRONIC VASCULAR, INC. (US) | 2009-12-03 | — | — | US | claimed |
| US-5892112-A | ACYLATION OF AMINO ACIDS WITH ANHYDRIDES OR CARBOXY GROUPS, AMIDATION WITH AMINE AND CONVERSION OF ACID OR ESTER TO HYDROXAMIC ACID AND HYDROLYSIS | GLYCOMED INCORPORATED (US) | 1999-04-06 | — | — | US | claimed |
| EP-0690841-A4 | SYNTHETIC MATRIX METALLOPROTEASE INHIBITORS AND USES THEREOF | GLYCOMED INC (US) | 1996-03-13 | — | — | EP | claimed |
| EP-0690841-A1 | SYNTHETIC MATRIX METALLOPROTEASE INHIBITORS AND USES THEREOF | GLYCOMED INCORPORATED (US) | 1996-01-10 | — | — | EP | claimed |
| WO-1995019965-A1 | SYNTHETIC MATRIX METALLOPROTEASE INHIBITORS AND USES THEREOF | GLYCOMED INCORPORATED (US) | 1995-07-27 | — | — | WO | claimed |
| CN-107106453-B | Skin lightening composition comprising niacinamide and ilomastat | 联合利华知识产权控股有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-107106454-B | Skin lightening compositions comprising 4-hexylresorcinol and ilomastat | 荷兰联合利华有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-9150865-B2 | Role of ADAM10 and its relevance to disease and therapeutics | THE UNIVERSITY OF CHICAGO (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | disclosed |
| US-20090299466-A1 | Local Delivery of Matrix Metalloproteinase Inhibitors | MEDTRONIC VASCULAR, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20040068015-A1 | Remedies for diseases due to stenotic lesions of blood vessel | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-1275385-A1 | REMEDIES FOR DISEASES DUE TO STENOTIC LESIONS OF BLOOD VESSEL | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | ADAM10, ADAM8, ADAM17 | MMP2 66/4885MMP9 28/4885MMP8 16/4885 |
| US-20040068015-A1 | Remedies for diseases due to stenotic lesions of blood vessel | MMP11, MMP1, MMP8 | MMP2 19/4885MMP9 4/4885MMP8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.